Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Laura Davis

Physician Assistant, Medical Salem, VA Physician Assistant

NPI 1154571446 CMS profile 10559723

100 Knotbreak Rd, Salem, VA 24153

Open in the dashboard

General payments

$8,106

377 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laura Davis of Salem, VA is reported in the CMS Open Payments database as having received $8,106 across 377 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,112 91
2024 General $1,288 62
2023 General $1,757 70
2022 General $1,543 79
2021 General $1,407 75

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Davis
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Laura Davis were reported at $2,112. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Laura Davis Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,407 $156 $41–$563 $132
2022 $1,543 $185 $55–$649 $149
2023 $1,757 $199 $58–$717 $160
2024 $1,288 $206 $62–$740 $164
2025 $2,112 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $3,625 113 payments
  2. AbbVie, Inc. $1,051 86 payments
  3. Boston Scientific Corporation $759 16 payments
  4. Collegium Pharmaceutical, Inc. $733 72 payments
  5. Pfizer Inc. $180 10 payments
  6. DePuy Synthes Sales Inc. $178 9 payments
  7. Merz Pharmaceuticals, LLC $170 6 payments
  8. SI-BONE, Inc. $148 6 payments
  9. Merck Sharp & Dohme Corporation $103 6 payments
  10. Teva Pharmaceuticals USA, Inc. $100 5 payments
  11. Other $1,060 48 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,106 377 payments
Products named General payments · program years 2021–2025
  1. INTELLIS ADAPTIVESTIM $1,132 21 payments
  2. QULIPTA $570 50 payments
  3. UBRELVY $548 50 payments
  4. BELBUCA $543 50 payments
  5. VANTA ADAPTIVESTIM $464 12 payments
  6. INTELLIS $416 15 payments
  7. Intracept Intracept Access Instruments (Gen 3)_NMOD $401 8 payments
  8. Accurian $386 19 payments
  9. INCEPTIV $373 8 payments
  10. Intracept Intracept Access Instruments (Gen 2)_NMOD $317 6 payments
  11. Other $3,516 177 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 60 drugs

Part D claims

12,587

Median for Physician Assistant: 241

Drug cost

$817,493

Median for Physician Assistant: $4,110

Branded share of claims

43.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 228 $152,334
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 2,711 $76,053
Oxycodone Hcl Generic 2,628 $70,306
Percocet Oxycodone Hcl/Acetaminophen Brand 13 $69,272
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 1,678 $64,506
Belbuca Buprenorphine Hcl Brand 71 $60,065
Oxycontin Oxycodone Hcl Brand 99 $54,833
Fentanyl Generic 260 $40,905
Oxymorphone Hcl Er Oxymorphone Hcl Brand 21 $37,476
Buprenorphine Generic 98 $30,677

The 10 drugs with the highest cost, of 60 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$104,597

Medicare's payments for the services billed

Medicare patients

443

Average age 67

Services billed

6,134

264 women, 179 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 73%
Depression 40%
Diabetes 38%
Ischemic heart disease 23%
COPD 23%
Chronic kidney disease 22%
Heart failure 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BELBUCA
  • Collegium Pharmaceutical, Inc. $162
$162 71 —
UBRELVY
  • AbbVie, Inc. $105
$105 — —
QULIPTA
  • AbbVie, Inc. $79
$79 17 —
Xeomin
  • Merz Pharmaceuticals, LLC $43
$43 — —
NURTEC ODT
  • PFIZER INC. $38
$38 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

377 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record